Mucopolysaccharidosis II - 50 Studies Found
Recruiting |
: Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome : Mucopolysaccharidosis II : 2014-10-02 : Drug: AGT-182 Recombinant HIRMAb-IDS |
Completed |
: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) : Mucopolysaccharidosis II : 2003-09-29 :
|
Completed |
: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients : Mucopolysaccharidosis II : 2011-02-22 :
|
Not yet recruiting |
: Study of Idursulfase-beta (GC1111) in Hunter Syndrome : Mucopolysaccharidosis II : 2016-01-17 :
|
Recruiting |
: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II : Mucopolysaccharidosis II : 2017-01-13 : Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor |
Completed |
: Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) : Mucopolysaccharidosis II : 1999-10-18 : Genetic: lymphocyte gene therapy |
Recruiting |
: A Study of JR-141 in Patients With Mucopolysaccharidosis Type II : Mucopolysaccharidosis II : 2017-04-10 : Drug: JR-141 IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week |
Recruiting |
: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients : Hunter Syndrome : 2014-01-19 |
Completed |
: A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 : Mucopolysaccharidosis II : 2012-05-17 :
|
Completed |
: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase :
|